Würzburg chemists have succeeded in controlling the passage of halide ions by deliberately introducing defects into a ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), ...

Short IONS slightly under 37.4, target 32.21, stop loss @ 37.51 Check the time stamp on this data. Updated AI-Generated ...

Ionis Pharmaceuticals, Inc. (IONS)股价已跌至52周新低,达到33.33美元的价格水平,该公司正面临充满挑战的市场环境。根据 InvestingPro 分析,尽管该公司显示出8.91的强劲流动比率,但其股票交易价格仍高于公允价值。市值为52.7亿美元的这家生物技术公司在过去一年里股价大幅下跌,较一年前下跌了34.69%。投资者正密切关注公司的表现,因为当前的市场条件 ...

Chemists have succeeded in controlling the passage of halide ions by deliberately introducing defects into a two-layer nanographene system. Their paper shows new perspectives for applications in water ...

A new analysis of data from the PHENIX experiment at the Relativistic Heavy Ion Collider (RHIC) reveals fresh evidence that collisions of even very small nuclei with large ones might create tiny ...

Physicists developed a method using hydrogen cations to control electronic properties in magnetic Weyl semimetals, enabling ...

RBC Capital analyst Luca Issi reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $70.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Used in everything from soda cans and foil wrap to circuit boards and rocket boosters, aluminum is the second-most-produced ...

Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/30.B7yWvFKE.js ...